TY - JOUR
T1 - In vitro antifungal activity of isavuconazole against Madurella mycetomatis
AU - Kloezen, Wendy
AU - Meis, Jacques F.
AU - Curfs-Breuker, Ilse
AU - Fahal, Ahmed H.
AU - Van De Sande, Wendy W.J.
PY - 2012/11
Y1 - 2012/11
N2 - Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.
AB - Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.
UR - http://www.scopus.com/inward/record.url?scp=84868021579&partnerID=8YFLogxK
U2 - 10.1128/AAC.01170-12
DO - 10.1128/AAC.01170-12
M3 - Article
C2 - 22964246
AN - SCOPUS:84868021579
SN - 0066-4804
VL - 56
SP - 6054
EP - 6056
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 11
ER -